Autolus Therapeutics plc (NASDAQ:AUTL) could be among the best stocks to invest in right now as the company shares are trading 5.67% or 0.85 points up from last closing price of $15, reaching $15.85 at last check. Any clue why there is so much of action in the AUTL stock? The share price has risen in 5 of the last 5 days and is up 44.93% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 64,632 shares, and in total 107932 shares valued at $1.711 million were seen changing hands compared with 43300 shares valued at $649500 recorded at the previous session. You should take into consideration that a greater volume on higher prices causes bullish signal for the market. It shows the sentiment is in an uptrend and more and more traders want to enter in the AUTL stock.
Autolus Therapeutics plc (AUTL) shares have notched a 3-month gain of about 44.93%, but has still tumbled -54.32% year to date. By comparison, the stock sank -62.43% over the past 12 months, while it jumped 24.9% over the 1 month. The company’s market cap is around $642.75M, with its short interest ratio standing at 5.53%.
In the current trading session for AUTL, the stock witnessed two major price actions, it rose to a high of $15.99 and was down as much as $14.67 at one point. The high recorded is very low when compared to their 52-week high which is $9.5. The 52-week high is now at -65.05 distance from current price. Their recent low of $44.95 represents a 65.37% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for AUTL is $33, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Autolus Therapeutics plc earned $-1.4 per share in the trailing 12 months and has a P/E ratio of -11.32. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 25.68 and lower compared to the sector’s average of 33.17. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. AUTL also has P/S multiple of 628.86. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.79x.
AUTL‘s last price was down -12.82% as compared to the average trading price of 50 days recorded at $18.18 while enlarging the period to 200 trading days, the average closing price was $12.72. At present, there are 42.85 million in the total number of common shares owned by the public and among those 8.82 million shares have been available to trade. The percentage of shares being held by the company management was 3.52% while institutions stake was 35.8%. The company has generated negative returns on equity over the last 12 months (0%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the AUTL stock, there is another set of technicals that should be looked into and considered. Its 22.42% gain from moving average of $12.95 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Autolus Therapeutics plc — 3 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $25 on shares of Autolus Therapeutics plc (NASDAQ:AUTL), which corresponds to 59.54% upside potential than its current market price of $15.85 and implies potential despite the recent advance in the price. However, their current target price has fallen from $33.33 a month ago and is down handily from the consensus target of $45.5 a quarter ago.
Let’s briefly check the hedge fund interest towards AUTL stock. Millennium Management LLC added position in the company after it grew 5033.4% or 27,197 shares of its common stock. The hedge fund now owns 1,396,142 shares worth $22,128,851, SEC documents show. Granahan Investment Management Inc. MA shored up assets in the stock as 275919.4 shares have been purchased, increasing its stake by 10.4% to 304,615 shares which are currently valued at $4,828,148. In addition, Barclays PLC recently reported that it now owns 3,195 shares making a total of $50,641 based on the recent price. This refelects a change of 7000% in their ownership.